Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. - Wikidata - wikimedia - TriplyDB

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

http://www.wikidata.org/entity/Q39779327

about

Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial.Evaluation of extended interval dosing aminoglycosides in the morbidly obese population Managing infective endocarditis in the elderly: new issues for an old disease."Random" gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens.The therapeutic monitoring of antimicrobial agents.Aminoglycosides: nephrotoxicity Once-daily aminoglycosides in the treatment of gram-positive endocarditis.Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.Outcomes in patients with gram-negative sepsis treated with gentamicin Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection A gentamicin order form improves its use Gentamicin dosing in critically ill patients.Investigational antimicrobial agents of 2013.Renal transport of antibiotics and nephrotoxicity: a review.Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.Ototoxicity induced by gentamicin and furosemide.Accuracy of empiric gentamicin dosing guidelines in neonates Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the Eu Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects Pharmacokinetics of ganciclovir and valganciclovir in the adult horse Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin.Risk factors for toxicity in elderly patients given aminoglycosides once daily.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Once-daily aminoglycosides in patients with neutropenic fever.Optimization of aminoglycoside therapy.Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods.Once-daily aminoglycoside therapy: potential ototoxicity.Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia.Therapeutic drug monitoring of antimicrobials.A meta-analysis and systematic review of the prevalence of mitochondrially encoded 12S RNA in the general population: Is there a role for screening neonates requiring aminoglycosides?Population pharmacokinetics of gentamicin in patients with cancer.Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.

P2860

Q28379292-A674EE69-15C2-4F6F-8417-660F9AC0AE2F Q28540814-816A5B6A-ADC9-4C87-BFA3-F9955C2AF794 Q29006722-9844FAB7-FFCC-4D52-B5E6-437C1149FD06 Q30245399-749BDBD6-8A27-4D91-AC25-19D953C2B8A6 Q33236907-96D114EB-548B-4B36-A79A-7A4885F400B3 Q33540451-057E6055-4382-4592-92F0-AF85F59F5723 Q33605648-463AF58B-08DA-4B23-B059-BA2E610B713F Q33659372-0388647F-8B6D-47E2-8DF0-D2AFA77C279A Q33692063-6DE95FF6-C031-416E-A4C1-096637203060 Q33949330-DAC9A955-85C7-4E82-A697-C63B5E51350F Q33977062-C600B0B5-9825-43DC-A157-2C7AE6CC0987 Q34141627-0D47880E-65C2-46DA-8216-9833168040C5 Q34188676-A87664F6-CD7F-400A-B318-05D72EF111F6 Q34291143-D64592D8-9019-4639-BFE2-5D24824E7EE9 Q34375204-39E2A964-56CE-4B8E-8ECB-816BDAEA5A1E Q34472677-B13D53B9-7C0C-4063-8697-3BA12F318EDA Q34476089-D224588F-0DAD-4B28-B6AE-7FDA8DB7CECA Q34521641-F42F4EBA-B93A-42AB-98FA-ADB88A470361 Q34589031-80653120-CAC1-43B0-BF83-B3C4C3A4670E Q34611253-FEAD9A6F-894A-4DA3-9D6C-E77845523A93 Q34632230-AA6883C8-2A8F-429F-BF2B-7AF379D57B6B Q34684840-4CA66159-A50C-419E-8409-D57A1C9BAC66 Q34694922-EB7B6C28-AC4E-4EC0-A4BA-7FF800B50659 Q34752229-945550F4-C43A-422B-A437-C4C290449BF8 Q34894900-280EF216-23B1-4F1E-9540-1A183EE39A4B Q34985783-ACF09B1B-904F-4509-8732-8D57099BA2F7 Q35005127-00A36F52-561D-4642-A29A-43F604698A5B Q35123348-B15C0C55-7F67-4EDF-BB15-60FE6725F851 Q35124299-C4C9817B-71C5-42B7-84BD-3E169D2384F2 Q35126312-EC5E6E44-048E-4803-BB02-CB827EBFBFC7 Q35127266-31EDE839-74BB-451C-9276-5E39C53DE3EE Q35127921-E46D7761-7188-4202-97E3-B78B98BC65DD Q35127932-03ABD321-D823-43A8-9403-F14C63097948 Q35135145-11151FBF-2290-4288-990E-73F01A2E2D3C Q35136143-E0DDC501-B96C-4298-A105-0E3AECFD88B7 Q35262273-44007F0B-EF5C-45C2-9B97-80B7F4FE54FD Q35640430-85870CA6-BDD4-4455-B8B1-9118B0060B5C Q35689759-B041C3BD-65AA-4C3A-9E73-1EB8EBB3D854 Q35802610-C7FAA7D9-8723-497C-88C2-F88AEB8C88FB Q35806154-235F9C2F-348F-4396-8377-6A1B9D990BC7

P2860

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

http://www.wikidata.org/entity/Q39779327

description

1995 nî lūn-bûn

@nan

1995年の論文

@ja

1995年学术文章

@wuu

1995年学术文章

@zh-cn

1995年学术文章

@zh-hans

1995年学术文章

@zh-my

1995年学术文章

@zh-sg

1995年學術文章

@yue

1995年學術文章

@zh

1995年學術文章

@zh-hant

name

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

@en

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

@nl

type

label

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

@en

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

@nl

prefLabel

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

@en

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

@nl

P1433

Q39779327-B3DDF367-9665-41AF-861F-8791183977C6

P1476

Q39779327-B6434F2A-A82D-4C4A-8768-BABC6C376A4F

P2093

Q39779327-10230D5B-ECA7-4211-9A80-D9DFE187AE2E

Q39779327-1BB1F2F0-9A45-4E57-91C9-01DCBA098AEB

Q39779327-377FEA34-BE48-40B0-89B5-CC2D2891C170

Q39779327-49A49C62-3CC4-46B7-BDF6-CACED7B9E424

Q39779327-754075A6-28D4-4976-90E0-14D52ABFB904

Q39779327-8D230F06-BD10-4A66-A116-D460902DE321

P2860

Q39779327-052257B8-01C7-4F5A-8D8B-22907865C18F

Q39779327-0AD8B2FF-BB02-48C3-9DBB-53E8D372CDAE

Q39779327-1DDCF905-0C59-492F-AAC9-36A5DBCF7ED9

Q39779327-214F439C-FB3E-497E-B19F-5D555ADAD369

Q39779327-225AB883-5625-4424-A6FC-359520D8ADDD

Q39779327-467AE22F-2D7B-489E-96F4-D7F61F89B183

Q39779327-74ADEE5C-501A-42B8-9F86-405B21C1FB46

Q39779327-8A250877-F942-4F27-96F6-939124C18DA8

Q39779327-ACBD0C78-48F0-43BD-9D15-CE8B8E8A7B5A

Q39779327-C494251D-E523-4C9D-A54F-C8CF6DEB28A6

P304

Q39779327-0A8943AB-5628-460E-93DA-CF1719224305

P31

Q39779327-396647A9-C4A9-4053-B570-FB10D4B28D31

P356

Q39779327-B44A6546-0326-4056-9B3C-B5F28EC0ED4A

P407

Q39779327-302A47F6-A81E-4F03-B765-15B1C0D0683D

P433

Q39779327-5C5F4017-054E-43A5-BEDE-236A7EA3D9ED

P478

Q39779327-A7D839F3-15C0-4F03-8562-9FF2F9448F72

P577

Q39779327-FB6D2930-5F30-4816-B5B5-8140DA69DC21

P5875

Q39779327-FDCC8A6D-2E90-41FA-9AF5-77C1C8851899

P698

Q39779327-4BBF79E2-D91E-44FB-90EA-02C579DDC56D

P921

Q39779327-8AD4109C-436D-43D0-A997-60DB20A3F3A6

P932

Q39779327-97F2F4AA-1CA3-4BAF-A7E0-D84E09BECA14

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

@en

P2093

Belliveau PP

http://www.w3.org/2001/XMLSchema#string

Freeman CD

http://www.w3.org/2001/XMLSchema#string

Nicolau DP

http://www.w3.org/2001/XMLSchema#string

Nightingale CH

http://www.w3.org/2001/XMLSchema#string

Quintiliani R

http://www.w3.org/2001/XMLSchema#string

Ross JW

http://www.w3.org/2001/XMLSchema#string

P2860

Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?

Prediction of creatinine clearance from serum creatinine

The postantibiotic effect: a review of in vitro and in vivo data.

A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies.

A critical reevaluation of the "therapeutic range" of aminoglycosides.

Once-daily aminoglycoside therapy

Killing and regrowth of bacteria in vitro: a review.

Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design.

Once versus thrice daily gentamicin in patients with serious infections.

Mechanism of bactericidal action of aminoglycosides.

P304

650-655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.39.3.650

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

1995-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15405073

http://www.w3.org/2001/XMLSchema#string

P698

7793867

http://www.w3.org/2001/XMLSchema#string

P921

P932

162599

http://www.w3.org/2001/XMLSchema#string